Tower Research Capital LLC TRC Sells 9,872 Shares of BioNTech SE (NASDAQ:BNTX)

Tower Research Capital LLC TRC lessened its holdings in BioNTech SE (NASDAQ:BNTX – Get Rating) by 87.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,405 shares of the company’s stock after selling 9,872 shares during the period. Tower Research Capital LLC TRC’s holdings in BioNTech were worth $190,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BNTX. Artisan Partners Limited Partnership raised its stake in BioNTech by 200.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,228,913 shares of the company’s stock worth $300,636,000 after acquiring an additional 1,487,687 shares during the period. BlackRock Inc. lifted its position in BioNTech by 25.9% in the first quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock worth $274,768,000 after buying an additional 331,101 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in BioNTech by 21.0% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,847,935 shares of the company’s stock worth $275,527,000 after buying an additional 321,110 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of BioNTech during the first quarter worth $42,711,000. Finally, First Trust Advisors LP lifted its position in shares of BioNTech by 62.0% during the first quarter. First Trust Advisors LP now owns 489,951 shares of the company’s stock worth $83,566,000 after purchasing an additional 187,569 shares during the last quarter. Institutional investors own 15.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on BNTX shares. TheStreet upgraded BioNTech from a “c+” rating to a “b-” rating in a research note on Wednesday, February 1st. UBS Group set a $168.00 price target on shares of BioNTech in a research note on Wednesday, February 1st. The Goldman Sachs Group dropped their price objective on shares of BioNTech from $177.00 to $156.00 and set a “neutral” rating on the stock in a report on Tuesday, January 31st. Bank of America raised shares of BioNTech from a “neutral” rating to a “buy” rating and set a $239.00 price target on the stock in a report on Thursday, December 15th. Finally, Berenberg Bank set a $300.00 price target on shares of BioNTech in a research note on Monday, January 30th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $206.69.

BioNTech Stock Performance

NASDAQ:BNTX opened at $131.54 on Tuesday. The firm has a 50 day simple moving average of $142.48 and a 200-day simple moving average of $147.30. BioNTech SE has a 1-year low of $117.08 and a 1-year high of $189.07. The firm has a market cap of $31.92 billion, a PE ratio of 2.97 and a beta of 0.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.37 and a quick ratio of 5.30.

BioNTech Profile

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.